Citigroup Maintains Neutral on Hims & Hers Health, Raises Price Target to $35

Benzinga Newsdesk www.benzinga.com Neutral 59.7%

Neg 0% Neu 59.7% Pos 0%

Citigroup analyst Daniel Grosslight maintains Hims & Hers Health (NYSE:HIMS) with a Neutral and raises the price target from $28 to $35.